MBX Biosciences, Inc.
As of Oct 22, 2026, MBX Biosciences is in Stage 3, the topping phase, now in week 3 (since Oct 7, 2026). It closed at $50.46, 28.6% below its 52-week high and above its 200-day average, which is rising.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is MBX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
MBX among Biotechnology20th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …20 | MBX | Stage 3 · wk 3 | 98 | −12.8% |
MBX Biosciences: quick answers
What stage is MBX Biosciences in?
As of Oct 22, 2026, MBX Biosciences (MBX) is in Stage 3, the topping phase. It entered Stage 3 on Oct 7, 2026 and is in week 3. What the four stages mean
Is MBX Biosciences in an uptrend?
Its uptrend has stalled. MBX Biosciences is in Stage 3, the topping phase that follows an advance. It trades 12.0% above its 200-day average, which is rising.
How far is MBX Biosciences from its 52-week high?
MBX Biosciences closed at $50.46 on Oct 22, 2026, 28.6% below its 52-week high of $70.70. Its 52-week low is $14.78.
How has MBX Biosciences performed over the past year?
As of Oct 22, 2026, MBX Biosciences is up 229.6% over the past year and up 65.2% so far in 2026.
Which sector and industry is MBX Biosciences in?
MBX Biosciences is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.